RetaCalc
Protocol library
BlendNot ApprovedMixedVery Low confidenceSourced

GLOW blend

A three-component GHK-Cu, BPC-157 and TB-500 research blend. No controlled human evidence establishes this combined formulation or schedule.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily for 4 weeks
Third-party educational schedule for a 70 mg GLOW blend

2.33 mg total daily for four weeks, approximately 1.67 mg GHK-Cu plus 0.33 mg BPC-157 and 0.33 mg TB-500 at the stated 50:10:10 ratio

The component split is blend-ratio arithmetic, not a controlled human dose. No study validates the combined formulation, route or four-week schedule.

View source

Evidence summary

A three-component GHK-Cu, BPC-157 and TB-500 research blend. No controlled human evidence establishes this combined formulation or schedule.

Protocol basis

The name describes a commercial combination, not a clinical development programme. The page therefore reports only the separate evidence boundaries of its components.

What remains uncertain

There are no matched human pharmacokinetic, compatibility, stability, safety or outcome data for the mixture.

Warnings and contraindications

No controlled human study of the three-component blend was identified.
Topical GHK-Cu evidence does not validate systemic use in a blend.
Component claims cannot demonstrate mixture stability, sterility or clinical benefit.